Special Issue

Immunotherapeutic Strategies for Precision Tumor Targeting

Message from the Guest Editors

Cancer immunotherapy requires the development of effective therapeutic strategies capable of eliciting an effective immune response to eradicate or control cancer. Traditional immunotherapeutic methods, such as immune checkpoint inhibitors and cancer vaccines, offer hope for enhancing the clinical response. However, even in combination with other standard therapies, including chemotherapy, there are significant challenges to its effectiveness, including immune cell exhaustion and cancer resistance, which eventually lead to relapse and death. A better understanding of the biology of the immune tumour microenvironment (TME), the enrichment and expansion of specific immune cells, such as tumour reactive T-cells, and the gene modification of immune cells are recent novel approaches to improving cancer immunotherapy. This Special Issue focuses on promising cancer immunotherapy strategies targeting the TME and beyond, including mRNA vaccines, adoptive cell therapies, such as TILs, CAR-T cell therapy, TCR therapy, immune checkpoint inhibitors, bispecific antibodies, immunomodulation strategies, and any new innovative methods that can stimulate specific tumor immune responses.

Guest Editors

Dr. Yien Ning Sophia Wong
Royal Marsden Hospital, 203 Fulham Road, London SW3 6JJ, UK

Dr. Alvin Lee
The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK

Deadline for manuscript submissions

closed (30 September 2024)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/191681

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI